What are the opening hours?

Monday 8am - 5pm Tuesday 9am - 5pm Wednesday 9am - 5pm Thursday 9am - 5pm Friday 9am - 5pm

Ametris - formerly ActiGraph

Home
United States
Pensacola, FL
Ametris - formerly ActiGraph

Ametris is pioneering the digital transformation of clinical research

01/23/2026

Conventional clinical outcome assessments may lack the sensitivity to detect meaningful changes in patient functioning, but digital endpoints offer new opportunities to advance clinical research and drug development. To help clinical teams better understand how digital health technology (DHT) can enhance their development programs, we’ve created a comprehensive library of Digital Endpoint Resource Guides across 10 therapeutic areas.

These Digital Endpoint Guides serve as foundational tools for researchers to help bridge the gap between DHT selection and successful trial ex*****on across a wide variety of therapeutic areas and indications.

Each Digital Endpoint guide in the library features:
🔎 Challenges and limitations of conventional assessments
🔎 Meaningful aspects of health and specific digital measures of relevance
🔎 Opportunities to improve trial outcomes with DHT
🔎 Existing clinical trial usage and evidence generated
🔎 Relevant regulatory guidances and perspectives

Visit the library to access the Digital Endpoint Guides that are relevant to your current or upcoming protocols using the link in the comments below ⬇️

01/22/2026

📣 Our first Digital Health Monthly webinar of 2026 is less than a week away! 📣

Register now to join us for: Introducing 6M95C, A Novel Digital Measure for Tracking Disease Progression in Duchenne Muscular Dystrophy (DMD)

During this webinar, we'll explore 6M95C, a novel digital measure that complements the regulatory-qualified SV95C measure by providing functional capacity assessments across all disease stages, including the non-ambulatory stages in patients with DMD and other neuromuscular diseases.

🗓 Date: Wednesday, January 28, 2026
⌛ Time: 12PM EST
🎙 Speakers:
▫️Jonathon Soslow, MD MSCI, Vanderbilt University Medical Center
▫️ Rakesh Pilkar, PhD, Lead of DHT Solutions, Ametris
▫️ Andrew Liu, PhD, Biostatistician, Ametris

👇Register via the link in the comments (includes on-demand recording)

01/21/2026

The Ametris team is heading to Orlando (Feb 2-5) for this year's SCOPE 2026 Summit, welcoming senior executives from pharma, biotech, and CROs to connect. Visit our team at exhibit booth #227 to learn more about our Ametris digital health technology (DHT) ecosystem.

If you’re looking to optimize your digital endpoint strategy or want to learn more about our end-to-end DHT platform and clinical trials experience, let’s talk at SCOPE! Reach out to Sarah Bell, Michael Philcock, Sean Smith, or Jon Lake, or schedule a meeting with a member of our team.

📅 Book a 1-on-1 meeting at the link in the comments below!

01/20/2026

Join us at the Ametris Digital Data Summit (ADDS 2026) in Atlanta, GA next month, where we'll host a dedicated session on Physical Activity and Mobility.

Led by scientific leaders from Pfizer, Roche, Northumbria University, and Columbia University, this session will dive into real-world examples of how continuous, digital measures of physical function and mobility are enabling clinical researchers to detect disease progression and earlier treatment signals across multiple therapeutic areas, including neurology, respiratory, and rare diseases.

🔎 One Step at a Time: the Winding Road to Measuring Physical Activity in Clinical Trials - Carrie Northcott, PhD, Pfizer

🔎 The Construct Validity of Real-World Digital Mobility Outcomes in People with Chronic Obstructive Pulmonary Disease: Results and a Digital Biomarker Validation Framework - Dimitrios Megaritis, PhD, Northumbria University

🔎 Utility of Digital Motor Score in Clinical Development in Neurology - Jonas Dorn, PhD, Roche

🔎 Digital Measures for Clinical Trial Endpoints in Huntington's Disease: the MEND-HD Study - Lori Quinn, PhD, Columbia University

To learn more about the ADDS 2026 agenda, speaker lineup, and registration details, visit the link in the comments below! 👇

01/13/2026

📣 We’re excited to announce a new pre-conference workshop at ADDS 2026 focused on advancing measurement in Huntington’s disease (HD) clinical trials.

As HD trials move into earlier stages of disease, commonly used clinical endpoints often lack the sensitivity and objectivity needed to efficiently detect treatment effects. These limitations can drive larger sample sizes, longer trials, and increase the risk of missing true drug signals.

This interactive workshop will bring together regulators, academic experts, industry leaders, and patient-focused organizations to explore how wearable technology and remote passive data collection can strengthen measurement strategies for HD clinical development. Taking place on Monday, February 23 from 1:00–5:00 PM ET, the session will feature speakers from the FDA, Columbia University, the University of Rochester Medical Center, Roche, the CHDI Foundation, and Ametris.

Workshop participants will align on evidence-generation priorities, assess gaps in current HD endpoints, and help shape a shared framework to guide future digital measurement development, with the goal of improving the rigor, relevance, and efficiency of HD clinical trials.

‼️Space is limited and available on a first-come basis. To reserve your spot, select the HD Pre-Conference Workshop option when you register for ADDS 2026. View the full agenda and register today using the link in the comments below.

01/09/2026

We hope you'll join us on January 28th for the first Digital Health Monthly webinar of 2026: Introducing 6M95C, A Novel Digital Measure for Tracking Disease Progression in Duchenne Muscular Dystrophy.

Accurately measuring disease progression across the full spectrum of Duchenne muscular dystrophy (DMD) remains a major challenge, especially as the disease progresses to a non-ambulatory stage. In a new study published in Pediatric Neurology, researchers introduce 6M95C, a novel accelerometry-based digital measure designed to complement the regulatory-qualified SV95C by capturing functional capacity across all disease stages, including in non-ambulatory patients.

During the webinar, several of the study authors, including Jonathon Soslow, MD MSCI of Vanderbilt University Medical Center and Ametris scientists Rakesh Pilkar and Andrew Liu, will discuss the development, validation, and clinical implications of 6M95C in DMD research.

⤵️Register now using the link in the comments below.

Can’t attend live? Register today, and you’ll receive the on-demand recording directly to your inbox.

01/08/2026

📣 New Suite of Digital Functional Capacity Measures for Neuromuscular Disorder Research!

Traditional functional assessments in neuromuscular disorder (NMD) research are most often episodic, effort-dependent, and limited to ambulatory patients. This means early signals can be missed and insight lost as the disease progresses.

To address these gaps and advance NMD research, Ametris has launched a new suite of digital measures designed to assess real-world functional capacity across all stages of NMD, including both ambulatory and non-ambulatory patients.

🔹 6M95C – A novel, accelerometry-based measure capturing peak movement over six minutes to track skeletal muscle function in ambulatory and non-ambulatory patients
🔹 SV95C – An EMA-qualified digital measure reflecting real-world walking performance, with proven sensitivity to meaningful change in Duchenne muscular dystrophy (DMD) and relevance across multiple NMDs

Together, 6M95C and SV95C enable continuous, real-world functional assessment and earlier detection of change across the full course of the disease, supporting stronger evidence generation in NMD research.

👉 Read the full product announcement linked below to explore the science, validation, and applications for these digital measures.

01/05/2026

🎉 Happy New Year!

Here at Ametris, 2025 was a year defined by growth, collaboration, and impact. In a new year-end blog reflection, Jeremy Wyatt, our CEO, looks back on key milestones and progress, from expanding our platform capabilities and rebranding as Ametris, to advancing digital evidence in oncology, launching DECODE Obesity, and growing the ADDS scientific community. Together, these efforts reinforced the importance of collaboration and rigor in digital measure adoption and inform our continued focus in 2026 on evidence generation and supporting clinical research.

👉 Read the full blog post using the link below.

12/31/2025

🚨Today is the last day for ADDS 2026 advanced pricing!

Join experts across clinical research, digital health, and life sciences at the ADDS 2026 Annual Scientific Conference, February 23–25 in Atlanta, GA.

ADDS 2026 brings together cutting-edge research and real-world applications of digital health technology across key areas including physical activity and mobility, sleep and scratch, AI, regulatory science, methodology and study design, and pharma innovation.

The program also features expert-led panel discussions, a dedicated scientific poster session, and multiple opportunities to connect with peers and collaborators across industry and academia.

👉 Register today to secure advanced pricing before it ends! Registration link in the comments below ⬇️

12/19/2025

⏰ ADDS 2026 Advance Pricing Ends December 31st!

Join leaders and experts across clinical research, digital health, and life sciences at the ADDS 2026 annual scientific conference, taking place February 23–25 in Atlanta, GA.

This year’s program highlights leading research and real-world applications across key areas of digital health, including:

🔹 Physical Activity & Mobility
🔹 Sleep & Scratch
🔹 Artificial Intelligence
🔹 Regulatory Science
🔹 Methodology & Study Design
🔹 Pharma Innovation

Plus, ADDS attendees will engage in expert-led panel discussions, explore emerging research during a dedicated scientific poster session, and connect with peers through numerous built-in networking opportunities designed to spark collaboration and insight.

Secure your spot before advance pricing ends and save $100! Registration link in the comments below ⬇️

12/16/2025

As regulatory engagement around digital health evolves, new opportunities are emerging to accelerate adoption in clinical research. At ADDS 2026, we'll host a dedicated ⭐Regulatory Session⭐ bringing together experts from FDA, Critical Path Institute, Eli Lilly and Company, and Ametris to explore how collaboration, evidence generation, and early engagement are shaping the next phase of digital health adoption. Presentation topics include:

✔️ Emerging approaches to regulatory engagement for digital health technologies
✔️ Lessons learned from real-world regulatory interactions
✔️ Opportunities for collaboration to support scalable, fit-for-purpose digital endpoints
✔️ Practical considerations for advancing adoption across therapeutic areas

We hope you’ll join us at ADDS 2026, Feb. 23-25 in Atlanta!

To learn more about ADDS 2026 and view the full agenda, visit the link in the comments below👇

Address

Pensacola, FL

Opening Hours

Monday	8am - 5pm
Tuesday	9am - 5pm
Wednesday	9am - 5pm
Thursday	9am - 5pm
Friday	9am - 5pm

Telephone

+18503327900

Website

http://www.ametris.com/

Alerts

Be the first to know and let us send you an email when Ametris - formerly ActiGraph posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Ametris - formerly ActiGraph:

Shortcuts

Address
Telephone
Opening Hours
Alerts
Contact The Practice
Claim ownership or report listing

Featured

Assisting Seniors LLC
32503

Want your practice to be the top-listed Clinic in Pensacola?

About Us

ActiGraph's innovative and extensively validated physical activity and sleep monitoring solutions deliver accurate, measurable insights into the real world physiological behaviors of subjects involved in academic research, population health studies, and clinical trials. Trusted by researchers and scientists in more than 90 countries, ActiGraph hardware and software products are the most widely used and extensively validated objective activity monitoring technology available.